Indian Origin Founders Anupam Lavania and Shilpa Malik’s Bioscan Research Raises $1 Million Seed Round Led by Unicorn India Ventures
What is the news?
Mumbai-headquartered medical technology company Bioscan Research has announced the successful closure of a $1 million seed funding round led by early-stage venture capital firm Unicorn India Ventures. Founded in 2017 by Indian origin founders Anupam Lavania and Shilpa Malik, Bioscan Research specializes in developing non-invasive hardware-software medical systems designed for rapid, point-of-care detection of traumatic brain injuries.
Why is it interesting?
The startup’s proprietary product, CEREBO, combines advanced Near-Infrared Spectroscopy (NIRS) with machine learning algorithms to identify intracranial bleeding. By detecting internal head trauma long before external symptoms manifest, the device equips emergency care providers and clinicians with critical diagnostic insights during the vital golden hour of medical intervention.
Having delivered a 5x growth performance over the previous year, Bioscan Research plans to utilize the newly acquired capital to upgrade its existing technology stack, secure global regulatory certifications, build new patent-protected IP, and drive international market entry. The investment underscores the rising momentum of deeptech startups within the global founders community building critical health solutions out of India for worldwide impact.
Read more: Medtech startup Bioscan Research raises $1 Mn in seed round led by Unicorn India Ventures